Company Overview and News

A fresh start for JF Technology

2018-09-21 theedgemarkets
AFTER being embroiled in a patent infringement lawsuit with rival Johnstech International Corp in the US over the past four years, high-performance test contacting solution provider JF Technology Bhd is ready to move on.
0146 BSMAF 1818

Tech: Jury still out on whether US-China trade war will benefit Malaysian semiconductor industry

2018-09-14 theedgemarkets
CHINA and the US are engaged in a trade war with both sides slapping tariffs on the other’s goods — ranging from steel, aluminium and cars to agricultural products — worth billions of dollars.
0146 0090

Trading ideas: Sapura Energy, CMS, Southern Steel, Dayang, Axiata

KUALA LUMPUR: JF Apex Research expects Sapura Energy Bhd , Cahya Mata Sarawak Bhd (CMSB), Southern Steel Bhd , Dayang Enterprise Holdings Bhd and Axiata Group Bhd to be among the stocks to watch on Monday.
4634 2852 0146 5665 6888 5141 AXXTF 7155

Stock With Momentum: JF Technology

2018-08-17 theedgemarkets
JF Technology Bhd (-ve) TRADING of shares in JF Technology (fundamental: 3/3, valuation: 1.10/3) triggered our momentum algorithm yesterday for the first time this year. The group saw 1,883,500 shares traded compared to its 200-day average of 105,782.5.

JF Tech sees gains from US-China trade conflict

2018-08-17 theedgemarkets
KUALA LUMPUR: Homegrown high-performance test contacting solutions provider, JF Technology Bhd (JF Tech) said it stands to benefit from the trade conflict between the US and China.

Choosing between JF Technology and FoundPac

2018-06-13 theedgemarkets
INVESTORS in semiconductor and semiconductor-related companies listed on Bursa Malaysia were laughing all the way to the bank following a surge in share prices last year. The likes of Unisem (M) Bhd, Globetronics Technology Bhd, Inari Amertron Bhd and Malaysian Pacific Industries Bhd (MPI), as well as ViTrox Corp Bhd, Elsoft Research Bhd, Aemulus Holdings Bhd and MMS Ventures Bhd climbed at least 50% to as much as 290% in 2017.
0166 0146 0113 3867 0090 0181 BSMAF 7022 GBTKF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...